Table 1 Characteristics of the patients with COVID-19

Age,median (IQR)

68.5

(56–74.3)

60

(50–73)

68

(56–74.8)

0.263

Sex, n (%)

    Male

107

(68)

10

(71)

97

(67)

    Female

51

(32)

4

(29)

47

(33)

0.756

BMI (kg/m2)(IQR)

25

(22.8–259)

24.1

(20.6–28.2)

25.2

(22.9–27.9)

0.345

P/F ratio after intubation (IQR)

203

(164–259)

213

(182.5–267)

198

(162.5–259.5)

0.343

APACHE ΙΙ score (IQR)

12

(9–14)

9

(5–13)

12

(9–15)

0.019

pre-existing diabetes, n (%)

44

(27.8)

1

(7)

43

(29.9)

0.07

HbA1c, median (IQR)

6.2

(5.8–7.2)

6.6

(6.0–7.8)

6.2

(5.8–7.2)

0.233

Intubation, n (%)

158

(100)

14

(100)

144

(100)

-

Anti-viral drug

  before admission

    Favipiravir, n(%)

51

(32)

0

(0)

51

(35)

-

  after admission

    Favipiravir, n(%)

86

(54)

14

(100)

72

(50)

-

    Remdesivir, n(%)

9

(6)

0

(0)

9

(6)

-

Steroid treatment

  before admission

    Dexamethasone, n (%)

57

(36)

0

(0)

57

(40)

-

    Methylprednisolone, n (%)

34

(22)

0

(0)

34

(24)

-

  after admission

    Methylprednisolone, n (%)

155

(98)

14

(100)

141

(98)

ECMO, n (%)

2

(1)

1

(7)

1

(1)

Mortality, n (%)

20

(13)

1

(7)

19

(13)

0.516